Precision oncology company Datar Cancer Genetics (DCG) announced on Thursday that the US Food and Drug Administration (FDA) has cleared its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumours.
CellDx-Tissue, a qualitative in vitro diagnostic (IVD) test, uses targeted Next-Generation Sequencing (NGS) of DNA and RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumour tissue of patients diagnosed with solid tumours. The assay evaluates 517 cancer-associated genes and is intended to provide information on somatic single nucleotide variants (SNVs), small insertions and deletions (InDels), ERBB2 gene amplification, and gene fusions involving ALK, RET and ROS1.
CellDx-Tissue is a single-site assay performed at Datar Cancer Genetics' CAP- and CLIA-accredited laboratory.
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
Poolbeg Pharma secures Canadian patent grant for POLB 001
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001